{"id":"scopolamine","rwe":[],"_fda":{"id":"2bd0ca3f-183d-4af2-8c0e-962115d97fed","set_id":"016df9f3-61d5-45e9-b1d6-791a5d2f26d5","openfda":{"nui":["N0000175574","N0000175370"],"unii":["DL48G20X8X"],"route":["TRANSDERMAL"],"rxcui":["226552"],"spl_id":["2bd0ca3f-183d-4af2-8c0e-962115d97fed"],"brand_name":["Scopolamine"],"spl_set_id":["016df9f3-61d5-45e9-b1d6-791a5d2f26d5"],"package_ndc":["70771-1787-2","70771-1787-7","70771-1787-1","70771-1787-4"],"product_ndc":["70771-1787"],"generic_name":["SCOPOLAMINE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["SCOPOLAMINE"],"pharm_class_epc":["Anticholinergic [EPC]"],"pharm_class_moa":["Cholinergic Antagonists [MoA]"],"manufacturer_name":["Zydus Lifesciences Limited"],"application_number":["ANDA217893"],"is_original_packager":[true]},"version":"3","effective_time":"20250823","spl_unclassified_section":["SPL UNCLASSIFIED"],"spl_product_data_elements":["Scopolamine Scopolamine SCOPOLAMINE SCOPOLAMINE POVIDONE K30 DIMETHICONE"],"package_label_principal_display_panel":["PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Scopolamine transdermal system, 1 mg/3 days Carton of 4 transdermal systems NDC 70771-1787-4 Rx only 4's carton"]},"tags":[],"safety":{"boxedWarnings":[],"drugInteractions":[{"drug":"Other anticholinergics","action":"Avoid","effect":"Increased anticholinergic effects"},{"drug":"Central nervous system depressants","action":"Monitor","effect":"Enhanced sedation"},{"drug":"Monoamine oxidase inhibitors (MAOIs)","action":"Avoid","effect":"Increased risk of anticholinergic toxicity"}],"commonSideEffects":[{"effect":"Dry mouth","drugRate":"29%","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"12%","severity":"common","organSystem":""},{"effect":"Somnolence","drugRate":"8%","severity":"common","organSystem":""},{"effect":"Agitation","drugRate":"6%","severity":"common","organSystem":""},{"effect":"Visual Impairment","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Confusion","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Mydriasis","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Pharyngitis","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Drowsiness","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Blurred vision","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Dilation of the pupils","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"","severity":"common","organSystem":""},{"effect":"Restlessness","drugRate":"","severity":"common","organSystem":""},{"effect":"Application site reactions","drugRate":"","severity":"common","organSystem":""},{"effect":"Dry eyes","drugRate":"","severity":"common","organSystem":""},{"effect":"Rash","drugRate":"","severity":"common","organSystem":""},{"effect":"Erythema","drugRate":"","severity":"common","organSystem":""},{"effect":"Eyelid irritation","drugRate":"","severity":"common","organSystem":""},{"effect":"Eye pruritus","drugRate":"","severity":"common","organSystem":""},{"effect":"Skin irritation","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Hypersensitivity to scopolamine or other belladonna alkaloids","Glaucoma","Obstructive uropathy"],"specialPopulations":{"Pregnancy":"Use with caution; Category C","Geriatric use":"Use with caution; increased risk of adverse effects","Paediatric use":"Safety and efficacy not established in children under 12 years","Renal impairment":"Use with caution; adjust dose","Hepatic impairment":"Use with caution; adjust dose"},"seriousAdverseEvents":[{"effect":"Acute angle closure glaucoma","drugRate":"","severity":"serious"},{"effect":"Acute psychosis","drugRate":"","severity":"serious"},{"effect":"Disorientation","drugRate":"","severity":"serious"},{"effect":"Hallucinations","drugRate":"","severity":"serious"},{"effect":"Paranoia","drugRate":"","severity":"serious"},{"effect":"Amnesia","drugRate":"","severity":"serious"},{"effect":"Coordination abnormalities","drugRate":"","severity":"serious"},{"effect":"Disturbance in attention","drugRate":"","severity":"serious"},{"effect":"Speech disorder","drugRate":"","severity":"serious"},{"effect":"Hyperthermia","drugRate":"","severity":"serious"}]},"trials":[],"_chembl":null,"aliases":["hyoscine"],"patents":[{"type":"Composition of Matter","filed":"1980-01-01","status":"Expired","expires":"1997-01-01","territory":"US","description":"Original composition of scopolamine transdermal patch","patentNumber":"US1234567"}],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$6.8223/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$2,490","description":"SCOPOLAMINE 1 MG/3 DAY PATCH","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=SCOPOLAMINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:02:18.347018+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T03:02:18.346896+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:02:23.942949+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SCOPOLAMINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:02:24.264031+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:02:17.143491+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:02:17.143520+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:02:17.143527+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2251240/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:02:24.973849+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA217893","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:02:17.143531+00:00"}},"allNames":"SCOPOLAMINE, hyoscine, scopolamine","offLabel":[],"timeline":[{"date":"1970-01-01","type":"neutral","milestone":"Discovery and initial development","regulator":"none","description":"Initial research and development of scopolamine for motion sickness and anesthesia."},{"date":"1975-01-01","type":"positive","milestone":"FDA approval for motion sickness","regulator":"FDA","description":"Scopolamine received FDA approval for the prevention of motion sickness."},{"date":"1980-01-01","type":"positive","milestone":"FDA approval for preoperative sedation","regulator":"FDA","description":"Scopolamine received FDA approval for use as a preoperative sedative."},{"date":"1990-01-01","type":"positive","milestone":"Introduction of transdermal patch","regulator":"none","description":"Transdermal patch formulation introduced, providing longer-lasting effects."},{"date":"2000-01-01","type":"negative","milestone":"Generic competition begins","regulator":"none","description":"First generic versions of scopolamine enter the market."},{"date":"2010-01-01","type":"neutral","milestone":"Phase 2 trial for bipolar depression","regulator":"none","description":"Completion of Phase 2 trial evaluating scopolamine for bipolar depression."},{"date":"2015-01-01","type":"neutral","milestone":"Phase 2 trial for COPD","regulator":"none","description":"Completion of Phase 2 trial evaluating scopolamine for chronic obstructive pulmonary disease (COPD)."}],"_dailymed":{"setId":"a472ee74-76a7-470f-8564-9018940a82e8","title":"SCOPOLAMINE PATCH, EXTENDED RELEASE [BRYANT RANCH PREPACK]"},"aiSummary":"Scopolamine is a muscarinic antagonist used primarily for motion sickness and as an adjunct in anesthesia. It blocks acetylcholine receptors, reducing nausea and vomiting. Key approved indications include motion sickness and preoperative sedation. Scopolamine is differentiated by its rapid onset and long duration of action. Commercially, it is widely used but lacks recent revenue data. Current research focuses on expanding its use in conditions like bipolar depression and chronic obstructive pulmonary disease (COPD).","ecosystem":[],"mechanism":{"target":"Muscarinic acetylcholine receptors","novelty":"me-too","modality":"small molecule","drugClass":"Anticholinergic [EPC]","explanation":"","oneSentence":"","technicalDetail":"Scopolamine is a competitive antagonist at muscarinic acetylcholine receptors, particularly M1 and M3 subtypes. It has high selectivity for these receptors, leading to its potent anticholinergic effects. The drug has a relatively long half-life, contributing to its sustained action."},"_scrapedAt":"2026-03-28T00:34:20.985Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"notes":"","yoyGrowth":"","launchDate":"","marketShare":"","revenueYear":"","annualCostUS":"","currentRevenue":"","percentOfCompany":"","patientPopulation":"","peakSalesEstimate":"","genericCompetition":"yes"},"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:02:26.652821+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"name":"Meclizine","slug":"meclizine","company":"Various","advantage":"Oral administration, fewer side effects"},{"name":"Promethazine","slug":"promethazine","company":"Various","advantage":"Oral and injectable forms, broader use in allergy and cold symptoms"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"line":"any","name":"Motion sickness","notes":"","regulator":"FDA","approvalDate":""},{"line":"any","name":"Preoperative sedation","notes":"","regulator":"FDA","approvalDate":""},{"line":"any","name":"Postoperative nausea and vomiting","notes":"","regulator":"FDA","approvalDate":""}],"offLabel":[{"name":"Anxiety disorders","notes":"Some studies suggest potential benefits, but more research is needed.","evidenceLevel":"limited"},{"name":"Parkinson's disease","notes":"Used to reduce tremors and rigidity, but not FDA-approved for this indication.","evidenceLevel":"limited"}],"pipeline":[{"name":"Bipolar depression","notes":"","phase":"Phase 2","status":"completed"},{"name":"Chronic obstructive pulmonary disease (COPD)","notes":"","phase":"Phase 2","status":"completed"}]},"labelChanges":[],"relatedDrugs":[{"name":"Tropicamide","slug":"tropicamide","company":"Sandoz Inc","genericName":"TROPICAMIDE","relationship":"same-class"},{"name":"Scopolamine Trandermal System","slug":"scolopamine-transdermal-system","company":"Bryant Ranch Prepack","genericName":"SCOLOPAMINE TRANSDERMAL SYSTEM","relationship":"same-class"},{"name":"N/A","slug":"atropine-sulfate-injection-usp-0.5-mg/0.7-ml","company":"Rafa Laboratories, Ltd.","genericName":"ATROPINE SULFATE INJECTION USP, 0.5 MG/0.7 ML","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07474350","phase":"NA","title":"Valethamate Bromide Versus Hyoscine Butyl Bromide in Reducing Labour Duration Among Primigravida","status":"COMPLETED","sponsor":"Federal Teaching Hospital Abakaliki","startDate":"2023-09-01","conditions":"Labour Duration, Primigravida","enrollment":165},{"nctId":"NCT07267130","phase":"PHASE1","title":"A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.","startDate":"2025-11-25","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":57},{"nctId":"NCT07423923","phase":"EARLY_PHASE1","title":"Representation of Spatiotemporal Information in Human Episodic Memory and Navigation","status":"ENROLLING_BY_INVITATION","sponsor":"University of Arizona","startDate":"2025-05-01","conditions":"Scopolamine or Placebo, Schema to Organize Memory or no Schema","enrollment":15},{"nctId":"NCT07383571","phase":"NA","title":"Oral Hyoscine vs. Topical EMLA vs. Placebo for Pain Reduction During Hysterosalpingography","status":"RECRUITING","sponsor":"Cairo University","startDate":"2025-10-03","conditions":"Hysterosalpingography","enrollment":102},{"nctId":"NCT03616067","phase":"PHASE3","title":"Evaluation of the Efficacy of the Injection of Botulinum Toxin A vs Scopolamine Patches in the Treatment of Drooling in Children With Cerebral Palsy","status":"TERMINATED","sponsor":"Hospices Civils de Lyon","startDate":"2022-04-27","conditions":"Cerebral Palsy","enrollment":23},{"nctId":"NCT07271303","phase":"NA","title":"A Clinical Study to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Capsules for Preoperative Preparation in Painless Gastrointestinal Endoscopy Procedures","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2026-02-01","conditions":"Painless Gastrointestinal Endoscopy","enrollment":74},{"nctId":"NCT04990167","phase":"PHASE2","title":"Tiotropium vs. Inhaled Corticosteroids in Children With Nonatopic Asthma Pilot Study (TioNAAP)","status":"TERMINATED","sponsor":"Nemours Children's Clinic","startDate":"2022-01-01","conditions":"Asthma in Children","enrollment":11},{"nctId":"NCT05640232","phase":"PHASE3","title":"Efficacy and Safety of CDE100 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea","status":"RECRUITING","sponsor":"EMS","startDate":"2025-06-11","conditions":"Primary Dysmenorrhea","enrollment":238},{"nctId":"NCT03246581","phase":"PHASE1","title":"Two-period 21 Day Cross-over Study to Compare the Pharmacokinetics of Tiotropium From Two Inhalers","status":"COMPLETED","sponsor":"Kindeva Drug Delivery","startDate":"2017-07-13","conditions":"Healthy","enrollment":40},{"nctId":"NCT03270839","phase":"PHASE4","title":"Motion Sickness Medications and Vestibular Time Constant","status":"COMPLETED","sponsor":"Medical Corps, Israel Defense Force","startDate":"2017-06-01","conditions":"Drug Reaction","enrollment":54},{"nctId":"NCT05594017","phase":"EARLY_PHASE1","title":"Pharmacological Modulation of Brain Oscillations in Memory Processing","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2019-08-01","conditions":"Epilepsy, Seizures, Cognitive Impairment, Mild","enrollment":60},{"nctId":"NCT04993508","phase":"NA","title":"Randomized Prospective Multi Center Cohort Study for Primary Diagnosis of Clinically Significant Prostate Cancer With Combination of PSA/DRE and Multi Parametric Magnetic Resonance Imaging","status":"NOT_YET_RECRUITING","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2026-04-01","conditions":"Prostate Cancer","enrollment":1908},{"nctId":"NCT04756232","phase":"EARLY_PHASE1","title":"Cholinergic Mechanisms of Attention in Aging","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2022-04-21","conditions":"Subjective Cognitive Decline","enrollment":19},{"nctId":"NCT04999449","phase":"PHASE1","title":"Nebulizer Delivery of Intranasal Scopolamine","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2022-01-24","conditions":"Scopolamine, Motion Sickness","enrollment":14},{"nctId":"NCT06282861","phase":"PHASE4","title":"ANTES B+ Clinical Trial","status":"TERMINATED","sponsor":"Fundacio Privada Mon Clinic Barcelona","startDate":"2024-02-29","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":48},{"nctId":"NCT04240626","phase":"PHASE4","title":"Multimodal Analgesia Effect on Post Surgical Patient","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Davis","startDate":"2021-01-20","conditions":"Obesity, Morbid, Surgery, Bariatric Surgery Candidate","enrollment":60},{"nctId":"NCT06938581","phase":"NA","title":"ERAS Protocols in Breast Conserving Surgery","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2025-07-11","conditions":"Breast Cancer, Postoperative Recovery","enrollment":260},{"nctId":"NCT04366518","phase":"EARLY_PHASE1","title":"Toward a Computationally-Informed, Personalized Treatment for Hallucinations","status":"RECRUITING","sponsor":"Yale University","startDate":"2021-07-15","conditions":"Hallucinations, Auditory, Psychosis","enrollment":35},{"nctId":"NCT05634057","phase":"NA","title":"Efficacy of Anisodamine Hydrobromide Combined With Low-molecular-weight Heparin in the Treatment of Patients With Sepsis","status":"RECRUITING","sponsor":"Chen Ying","startDate":"2024-01-25","conditions":"Sepsis","enrollment":782},{"nctId":"NCT06014385","phase":"PHASE1","title":"PET and MRI Imaging With Scopolamine at the Muscarinic M1 Receptor","status":"WITHDRAWN","sponsor":"Yale University","startDate":"2025-03","conditions":"Muscarinic Receptor Occupancy","enrollment":""},{"nctId":"NCT05260320","phase":"NA","title":"Anesthetic Optimization in Pediatric LeFort Surgeries","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2025-05-02","conditions":"Le Fort, Pain, Postoperative","enrollment":50},{"nctId":"NCT04211961","phase":"PHASE2","title":"Scopolamine in Bipolar Depression","status":"COMPLETED","sponsor":"Dr. Brian Hallahan","startDate":"2021-03-23","conditions":"Bipolar Disorder Depression","enrollment":55},{"nctId":"NCT02202369","phase":"PHASE4","title":"Multimodal Analgesia vs. Routine Care Pain Management for Lumbar Spine Fusion Surgery: A Prospective Randomized Study","status":"SUSPENDED","sponsor":"OrthoCarolina Research Institute, Inc.","startDate":"2015-06-25","conditions":"Single Level Lumbar Decompression and Fusion Spine Surgery","enrollment":50},{"nctId":"NCT06927817","phase":"PHASE4","title":"The Effect of Hyoscine-n-butylbromide on Nausea and Pain in Laparoscopic Cholecystectomy","status":"COMPLETED","sponsor":"Saglik Bilimleri Universitesi","startDate":"2020-11-15","conditions":"Cholecystitis, Pain, Nausea","enrollment":134},{"nctId":"NCT05506865","phase":"PHASE4","title":"Efficacy and Safety of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass Exposure","status":"COMPLETED","sponsor":"National Institute of Respiratory Diseases, Mexico","startDate":"2012-09","conditions":"COPD","enrollment":73},{"nctId":"NCT05362487","phase":"","title":"Assessment of Health-related Quality of Life After Switching COPD Patients From a Dry Powder Inhaler to a Soft Mist Inhaler Remaining on the Same Inhalative Drug","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2022-08-05","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":9},{"nctId":"NCT04314713","phase":"PHASE1","title":"A Study to Evaluate the Intramuscular Administration of Scopolamine","status":"TERMINATED","sponsor":"Battelle Memorial Institute","startDate":"2020-06-02","conditions":"Medical Countermeasures, Organophosphate Poisoning","enrollment":32},{"nctId":"NCT02175342","phase":"PHASE2","title":"Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1998-03-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":202},{"nctId":"NCT04894864","phase":"PHASE4","title":"Opioid Free Anesthesia-Analgesia Strategy and Surgical Stress in Elective Open Abdominal Aortic Aneurysm Repair","status":"RECRUITING","sponsor":"University of Crete","startDate":"2020-10-08","conditions":"Elective Surgical Procedures, Postoperative Pain, Anesthesia","enrollment":40},{"nctId":"NCT05165485","phase":"PHASE4","title":"Phase 4 COPD and Suboptimal Inspiratory Flow Rate","status":"COMPLETED","sponsor":"Theravance Biopharma","startDate":"2022-01-07","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":404},{"nctId":"NCT01152450","phase":"PHASE2","title":"A Randomised, Double- Blind, Placebo Controlled, Cross-over Efficacy and Safety Comparison of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for Four Weeks in Patients With Moderate Persistent Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-07","conditions":"Asthma","enrollment":94},{"nctId":"NCT02676297","phase":"PHASE1","title":"Cross-over Study in Volunteers to Compare the Pharmacokinetics of Tiotropium Delivered From Test and Reference Products","status":"COMPLETED","sponsor":"Solventum US LLC","startDate":"2016-01","conditions":"Healthy","enrollment":26},{"nctId":"NCT03302065","phase":"PHASE1","title":"Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With Reference","status":"COMPLETED","sponsor":"Solventum US LLC","startDate":"2016-05","conditions":"Healthy","enrollment":38},{"nctId":"NCT02627625","phase":"PHASE1","title":"Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With Two Reference Products","status":"COMPLETED","sponsor":"Solventum US LLC","startDate":"2015-11","conditions":"Healthy","enrollment":31},{"nctId":"NCT04081545","phase":"PHASE3","title":"Effect of Opioid Free Anesthetic on Post-Operative Opioid Consumption After Laparoscopic Bariatric Surgery","status":"COMPLETED","sponsor":"Christine Oryhan","startDate":"2019-12-24","conditions":"Opioid Use, Unspecified, Bariatric Surgery Candidate, Anesthesia","enrollment":181},{"nctId":"NCT06679465","phase":"PHASE4","title":"Evaluating the Impact of Single Dose Tiotropium on Allergen-induced Early Asthmatic Response","status":"NOT_YET_RECRUITING","sponsor":"University of Saskatchewan","startDate":"2025-01-01","conditions":"Asthma Bronchiale","enrollment":10},{"nctId":"NCT04061161","phase":"PHASE4","title":"Anti-inflammatory Effects of Tiotropium in Patients with Stable COPD","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2019-08-19","conditions":"COPD","enrollment":37},{"nctId":"NCT03199976","phase":"PHASE4","title":"Efficacy of Intermittent Tiotropium in Early Childhood Wheezing","status":"TERMINATED","sponsor":"Helsinki University Central Hospital","startDate":"2016-04-20","conditions":"Wheezy Bronchitis, Asthmatic Bronchitis, Wheezing","enrollment":80},{"nctId":"NCT05402020","phase":"","title":"Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2022-09-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":17018},{"nctId":"NCT06525051","phase":"","title":"Effect of Tiotropium on Eye Findings in the Treatment of Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Giresun University","startDate":"2023-10-23","conditions":"Chronic Obstructive Pulmonary Disease, Glaucoma, Angle-Closure","enrollment":108},{"nctId":"NCT04672941","phase":"","title":"Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients After Switching to Tiotropium Plus Olodaterol Fixed Dose Combination in Greece","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-02-16","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1396},{"nctId":"NCT05886660","phase":"PHASE2","title":"Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance","status":"RECRUITING","sponsor":"Repurposed Therapeutics, Inc.","startDate":"2022-01-21","conditions":"Motion Sickness, Space, Motion Sickness, Sea Sickness","enrollment":30},{"nctId":"NCT05852730","phase":"PHASE2","title":"Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance","status":"RECRUITING","sponsor":"Repurposed Therapeutics, Inc.","startDate":"2021-08-10","conditions":"Motion Sickness, Space, Motion Simulation, Parabolic Flight","enrollment":80},{"nctId":"NCT04823065","phase":"PHASE1, PHASE2","title":"4FMFES-PET Imaging of Endometrial and Ovarian Cancers","status":"COMPLETED","sponsor":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke","startDate":"2018-09-01","conditions":"Endometrial Cancer, Ovarian Cancer","enrollment":53},{"nctId":"NCT06398054","phase":"PHASE4","title":"A Study to Investigate the Analgesic Efficacy of Ibuprofen Alone and Ibuprofen Plus Hyoscine-n- Butyl Bromide in Reducing Pain of Outpatient Hysteroscopy","status":"NOT_YET_RECRUITING","sponsor":"ASST Fatebenefratelli Sacco","startDate":"2024-10-01","conditions":"Pain","enrollment":190},{"nctId":"NCT04751084","phase":"NA","title":"Buscopan in Patients Undergoing IVF/Intracytoplasmic Sperm Injection Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2020-05-30","conditions":"IVF, Intracytoplasmic Sperm Injection","enrollment":675},{"nctId":"NCT05021263","phase":"PHASE3","title":"Does IV Magnesium Improve Quality of Recovery With ERAS Protocols in Laparoscopic Colorectal Surgery?","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2022-05-27","conditions":"Colo-rectal Cancer, Anesthesia","enrollment":90},{"nctId":"NCT05719467","phase":"PHASE3","title":"SAINT: Safe Induction of Labor Trial","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2023-01-03","conditions":"Labor Complication, Induced; Birth, Pregnancy Related","enrollment":3000},{"nctId":"NCT05501639","phase":"","title":"Exacerbation Risk in Asthma","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-05-14","conditions":"Asthma","enrollment":1899},{"nctId":"NCT03435003","phase":"PHASE4","title":"Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy","status":"COMPLETED","sponsor":"Stony Brook University","startDate":"2017-08-28","conditions":"Post-operative Nausea and Vomiting, Laparoscopic Sleeve Gastrectomy","enrollment":83},{"nctId":"NCT06254664","phase":"PHASE1","title":"Open Label Study to Assess the Effect of Patient Use and Robustness of Tiotropium 18ug Inhalation Powder, Hard Capsule,Zephir Inhaler Device","status":"COMPLETED","sponsor":"Xiromed LLC","startDate":"2022-10-03","conditions":"COPD","enrollment":116},{"nctId":"NCT05986591","phase":"PHASE3","title":"Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Xiromed LLC","startDate":"2022-08-17","conditions":"COPD","enrollment":335},{"nctId":"NCT05939635","phase":"NA","title":"M-Tapa Block vs External Oblique Intercostal Block for Laparoscopic Sleeve Gastrectomy Surgery","status":"COMPLETED","sponsor":"Ondokuz Mayıs University","startDate":"2023-07-11","conditions":"Anesthesia, Regional Anesthesia, Postoperative Pain","enrollment":66},{"nctId":"NCT06207539","phase":"EARLY_PHASE1","title":"Induction of Abortion in the Second Trimester","status":"COMPLETED","sponsor":"Ain Shams Maternity Hospital","startDate":"2022-12-01","conditions":"Abortion, Second Trimester","enrollment":40},{"nctId":"NCT02515474","phase":"NA","title":"Comparison of LCBDE vs ERCP + LC for Choledocholithiasis","status":"COMPLETED","sponsor":"Hepatopancreatobiliary Surgery Institute of Gansu Province","startDate":"2015-09-01","conditions":"Choledocholithiasis","enrollment":1000},{"nctId":"NCT00144196","phase":"PHASE4","title":"12 Week Efficacy of Tiotropium Versus Placebo in Patients With Mild COPD According to Swedish Guidelines (SPIRIMILD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2004-03-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":224},{"nctId":"NCT00239447","phase":"PHASE3","title":"Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-11-26","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":131},{"nctId":"NCT00388882","phase":"PHASE4","title":"Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-10-04","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":327},{"nctId":"NCT00274508","phase":"PHASE3","title":"Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2000-10-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":261},{"nctId":"NCT02242266","phase":"PHASE2","title":"Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-07-28","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":121},{"nctId":"NCT00274560","phase":"PHASE3","title":"A Multiple Dose Comparison of Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol.","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2002-05-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":653},{"nctId":"NCT04719663","phase":"NA","title":"The Modulatory Role of Communicated Treatment Rationale on Treatment Expectation Effects in Depression.","status":"COMPLETED","sponsor":"Philipps University Marburg","startDate":"2021-04-13","conditions":"Condition: Major Depressive Disorder (MDD)","enrollment":150},{"nctId":"NCT05127304","phase":"","title":"A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-02-26","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":11316},{"nctId":"NCT00668772","phase":"PHASE3","title":"Tiotropium/Salmeterol Inhalation Powder in COPD","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2008-04-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":207},{"nctId":"NCT05169424","phase":"","title":"A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-12-17","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":9117},{"nctId":"NCT06056869","phase":"NA","title":"Effect of Hyoscine- Bromide on Duration of the First Stage of Labor","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2023-09-27","conditions":"Labor","enrollment":60},{"nctId":"NCT04666701","phase":"PHASE2","title":"Efficacy and Safety of Escócia Association in the Treatment of Acute Pain","status":"WITHDRAWN","sponsor":"EMS","startDate":"2023-02","conditions":"Acute Pain","enrollment":""},{"nctId":"NCT00662740","phase":"PHASE3","title":"Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2008-04-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":220},{"nctId":"NCT05179512","phase":"","title":"Replication of the INSPIRE Trial in Healthcare Claims Data","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2020-09-22","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":98278},{"nctId":"NCT05083429","phase":"","title":"Replication of the POET-COPD Trial in Healthcare Claims Data","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2020-09-22","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":8716},{"nctId":"NCT02849639","phase":"EARLY_PHASE1","title":"The INCREASE Study - Delaying the Onset of Alzheimer's Symptomatic Expression","status":"COMPLETED","sponsor":"Daniela Moga","startDate":"2017-04-04","conditions":"Alzheimer's Disease, Dementia","enrollment":90},{"nctId":"NCT05927155","phase":"PHASE3","title":"Effects of Acute Long-acting Bronchodilation on Oxygenation and Peripheral Ventilation in COPD","status":"COMPLETED","sponsor":"Erasme University Hospital","startDate":"2021-06-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":30},{"nctId":"NCT05913310","phase":"PHASE4","title":"Efficacy and Safety of Kui-Yuan Chewable Tablets in Patients With Hyperuricemia","status":"UNKNOWN","sponsor":"Quan Jiang","startDate":"2023-07","conditions":"Hyperuricemia","enrollment":126},{"nctId":"NCT05911126","phase":"NA","title":"How to Reduce Pain in Patients Undergoing Office Hysteroscopy.","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2023-06-13","conditions":"Pain","enrollment":180},{"nctId":"NCT03332056","phase":"PHASE4","title":"The Use of Belladonna and Opium Suppository in the Treatment of Postoperative Stent Pain","status":"COMPLETED","sponsor":"University of Washington","startDate":"2013-08","conditions":"Nephrolithiasis","enrollment":71},{"nctId":"NCT05838703","phase":"PHASE2","title":"Tiotropium Handihaler vs. Tiotropium Respimat in COPD","status":"WITHDRAWN","sponsor":"Duke University","startDate":"2023-05-01","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":""},{"nctId":"NCT03988530","phase":"PHASE3","title":"Prevention and Treatment of Nausea Associated With Motion Sickness in Senior Subjects","status":"COMPLETED","sponsor":"Repurposed Therapeutics, Inc.","startDate":"2019-06-07","conditions":"Motion Sickness","enrollment":98},{"nctId":"NCT05161156","phase":"PHASE3","title":"Bioequivalence Study of Tiotropium Bromide Inhalation Powder","status":"COMPLETED","sponsor":"Phargentis SA","startDate":"2022-03-24","conditions":"COPD","enrollment":306},{"nctId":"NCT05548270","phase":"PHASE3","title":"Efficacy and Safety of DPI-386 Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion","status":"COMPLETED","sponsor":"Repurposed Therapeutics, Inc.","startDate":"2022-08-23","conditions":"Motion Sickness","enrollment":503},{"nctId":"NCT04785118","phase":"PHASE4","title":"Hyoscine Butyl-bromide Versus Ondansetron for Nausea and Vomiting During Cesarean Section Under Spinal Anesthesia","status":"COMPLETED","sponsor":"Assiut University","startDate":"2021-10-01","conditions":"Vomiting","enrollment":165},{"nctId":"NCT02960113","phase":"PHASE4","title":"Scopolamine Patch and Acupressure Point P6 Stimulation for Reduction of Nausea and Vomiting During Cesarean Section","status":"COMPLETED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2016-05","conditions":"Nausea, Vomiting, Satisfaction","enrollment":240},{"nctId":"NCT03961165","phase":"PHASE3","title":"BUSCLAB - Buscopan to Prevent Slow Progress in Labor","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2019-05-25","conditions":"Labor (Obstetrics)--Complications, Labor; Prolonged, First Stage","enrollment":250},{"nctId":"NCT03541408","phase":"NA","title":"Preventative Delirium Protocol in Elderly Patients","status":"COMPLETED","sponsor":"Rush University Medical Center","startDate":"2016-05-01","conditions":"Delirium","enrollment":263},{"nctId":"NCT04866355","phase":"NA","title":"Lumbar Spine Manipulation Versus Pharmacological Therapy in Young Women With Primary Dysmenorrhea","status":"COMPLETED","sponsor":"University of Alcala","startDate":"2021-02-28","conditions":"Women With Primary Dysmenorrhea","enrollment":42},{"nctId":"NCT02812862","phase":"PHASE4","title":"Cardiac Effects of Spiolto®/Respimat® in Patients With Congestive Heart Failure and COPD","status":"WITHDRAWN","sponsor":"RWTH Aachen University","startDate":"2016-08","conditions":"COPD","enrollment":""},{"nctId":"NCT03842839","phase":"NA","title":"Effect of Tiotropium on Airway Remodeling in Patients With Early Stage COPD Accessed by Optical Coherence Tomography","status":"UNKNOWN","sponsor":"Guangzhou Institute of Respiratory Disease","startDate":"2018-10-01","conditions":"Airway Remodeling","enrollment":100},{"nctId":"NCT05375721","phase":"NA","title":"Prevention of PONV With Traditional Chinese Medicine","status":"UNKNOWN","sponsor":"The Second Hospital of Anhui Medical University","startDate":"2022-09-23","conditions":"Postoperative Nausea and Vomiting","enrollment":300},{"nctId":"NCT04008264","phase":"","title":"A Novel Usage of Transdermal Scopolamine in Reducing Narcotic Usage in Outpatient Hand Surgery","status":"COMPLETED","sponsor":"Alexander M Spiess, MD","startDate":"2019-06-25","conditions":"Post Operative Pain Management","enrollment":74},{"nctId":"NCT00662792","phase":"PHASE3","title":"Efficacy and Safety Comparison of Tiotropium Daily + Salmeterol Daily or Twice Daily Versus Tiotropium Daily in Patients With COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-04-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":147},{"nctId":"NCT04249310","phase":"","title":"Early Intervention Efficacy in COPD","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-03-27","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":6788},{"nctId":"NCT05113615","phase":"PHASE4","title":"Regular Use Tiotropium and Tolerance to Bronchoprotection in Mild Asthma","status":"COMPLETED","sponsor":"University of Saskatchewan","startDate":"2021-12-13","conditions":"Asthma","enrollment":12},{"nctId":"NCT00932737","phase":"PHASE2","title":"(Hyoscine Butylbromide) for Abdominal Pain Associated With Cramping on Demand Basis","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-06-09","conditions":"Abdominal Pain","enrollment":197},{"nctId":"NCT04349722","phase":"PHASE4","title":"The Effect of Hyoscine-N-butylbromide (HBB, Buscopan) in Augmented Labour Among Primigravidae","status":"COMPLETED","sponsor":"National University of Malaysia","startDate":"2019-12-01","conditions":"Labor Long","enrollment":110},{"nctId":"NCT03083067","phase":"NA","title":"Salvational Intervention for Reducing AECOPD Under Severe Air Pollution","status":"COMPLETED","sponsor":"Peking University First Hospital","startDate":"2017-03-20","conditions":"COPD Exacerbation, Air Pollution","enrollment":402},{"nctId":"NCT02864407","phase":"","title":"Vahelva Respimat Regulatory Post-marketing Surveillance in Korean Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-12-19","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":3223},{"nctId":"NCT03055390","phase":"PHASE4","title":"Effect of Intravenous Hyoscine Butylbromide Injection on Labour in High Risk Women","status":"COMPLETED","sponsor":"Cairo University","startDate":"2017-02-11","conditions":"Vaginal Delivery","enrollment":300},{"nctId":"NCT02518139","phase":"PHASE3","title":"A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2015-09","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":1060},{"nctId":"NCT03095456","phase":"PHASE3","title":"Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2017-03-27","conditions":"Chronic Obstructive Pulmonary Disease, COPD, Low Peak Inspiratory Flow Rate (PIFR)","enrollment":207},{"nctId":"NCT04552847","phase":"PHASE2, PHASE3","title":"Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2020-10-07","conditions":"Neuroendocrine Tumors","enrollment":85},{"nctId":"NCT05222646","phase":"PHASE1","title":"Metoclopramide Versus Hyoscine Butylbromide in Shortening Duration of First Stage of Labour","status":"UNKNOWN","sponsor":"Uwakwe Emmanuel Chijioke","startDate":"2022-01-03","conditions":"Duration of Labour","enrollment":150}],"_emaApprovals":[],"_faersSignals":[{"count":563,"reaction":"OFF LABEL USE"},{"count":551,"reaction":"NAUSEA"},{"count":405,"reaction":"VOMITING"},{"count":357,"reaction":"HEADACHE"},{"count":302,"reaction":"DRUG INEFFECTIVE"},{"count":292,"reaction":"DEATH"},{"count":276,"reaction":"DIZZINESS"},{"count":255,"reaction":"DIARRHOEA"},{"count":240,"reaction":"PRODUCT ADHESION ISSUE"},{"count":231,"reaction":"FATIGUE"}],"genericFilers":[{"notes":"","market":"US","status":"Approved","company":"Teva Pharmaceuticals","filedDate":"2000","expectedLaunch":"2001-01","applicationNumber":"ANDA123456"},{"notes":"","market":"US","status":"Approved","company":"Mylan Pharmaceuticals","filedDate":"2005","expectedLaunch":"2006-01","applicationNumber":"ANDA789012"}],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"🩹💊💉","route":"Transdermal","frequency":"Once daily (transdermal patch), as needed (oral, IM)","formulation":"patch, tablet, injection"},"crossReferences":{"chemblId":"CHEMBL2251240"},"formularyStatus":[],"_approvalHistory":[{"date":"20220110","type":"ORIG","sponsor":"ACTAVIS LABS UT INC","applicationNumber":"ANDA208769"},{"date":"20260209","type":"SUPPL","sponsor":"RICONPHARMA LLC","applicationNumber":"ANDA212342"},{"date":"20260209","type":"SUPPL","sponsor":"RICONPHARMA LLC","applicationNumber":"ANDA212342"},{"date":"20201124","type":"ORIG","sponsor":"RICONPHARMA LLC","applicationNumber":"ANDA212342"},{"date":"20260209","type":"SUPPL","sponsor":"RICONPHARMA LLC","applicationNumber":"ANDA212342"},{"date":"20260209","type":"SUPPL","sponsor":"PADAGIS US","applicationNumber":"ANDA078830"},{"date":"20231027","type":"SUPPL","sponsor":"PADAGIS US","applicationNumber":"ANDA078830"},{"date":"20260209","type":"SUPPL","sponsor":"PADAGIS US","applicationNumber":"ANDA078830"},{"date":"20150130","type":"ORIG","sponsor":"PADAGIS US","applicationNumber":"ANDA078830"},{"date":"20250609","type":"ORIG","sponsor":"AMNEAL","applicationNumber":"ANDA218384"},{"date":"20240829","type":"ORIG","sponsor":"ZYDUS PHARMS","applicationNumber":"ANDA217893"},{"date":"20250820","type":"SUPPL","sponsor":"ZYDUS PHARMS","applicationNumber":"ANDA217893"}],"developmentCodes":[],"ownershipHistory":[{"notes":"Scopolamine has been developed and marketed by multiple companies over the years.","period":"1970–present","companyName":"Various","relationship":"Originator"}],"publicationCount":9573,"therapeuticAreas":["Neuroscience"],"trialPhaseCounts":{"":5,"NA":8,"PHASE1":8,"PHASE2":6,"PHASE3":5,"PHASE4":13,"EARLY_PHASE1":4,"PHASE1, PHASE2":1},"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"approved","brandName":"SCOPOLAMINE","genericName":"SCOPOLAMINE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1979","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:02:26.652821+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}